在晚期头部和部状细胞癌中与全身疗法结合重定位潘托普拉:一项I/II期随机 randomised研究
Vanita Noronha1, Vijay Patil2, Nandini Menon1
1Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Medical oncology (Northwood, London, England)
|December 22, 2023
概括
将静脉注射的潘托普拉添加到缓性化疗中,并没有改善头部和部状细胞癌患者的无进展生存率. 该研究发现,接受潘托普拉的患者在生存率或反应率方面没有显著的益处.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 像潘托普拉这样的质子抑制剂可以通过降低瘤酸度来增强癌症治疗.
- 这项研究调查了潘托普拉在改善头部和部状细胞癌 (HNSCC) 的结果方面的潜力.
研究的目的:
- 评估添加静脉注射潘托普拉到先进HNSCC的第一线息化疗的安全性和有效性.
主要方法:
- 进行了I/II期随机对照试验.
- 第一阶段确定了输入式潘托普拉 (240毫克) 的最大安全剂量.
- 第二阶段随机对120名HNSCC患者进行了用IV潘托普拉或不使用IV潘托普拉的化疗,评估了无进展生存期 (PFS).
主要成果:
- 添加潘托普拉没有显著延长PFS (2.2个月相比2.5个月).
- 响应率 (8.5%对6.6%) 和整体存活时间 (5.6个月对5.4个月) 在各组之间相似.
- 在等级≥3毒性中没有观察到显著差异.
结论:
- 静脉注射的潘托普拉240毫克添加到全身疗法并没有改善晚期HNSCC患者的结果.
- 潘托普拉在这个患者群体中不会增强息化疗的疗效.
更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.8K
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.8K
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
208
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
208
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
167
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
167
